 | • レポートコード：QYR2104Z1326 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・慢性閉塞性肺疾患（COPD）の市場動向 ・企業の競争状況、市場シェア ・慢性閉塞性肺疾患（COPD）の種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、その他） ・慢性閉塞性肺疾患（COPD）の用途別市場規模（病院、クリニック、その他） ・慢性閉塞性肺疾患（COPD）の北米市場規模2016-2027（アメリカ、カナダ） ・慢性閉塞性肺疾患（COPD）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・慢性閉塞性肺疾患（COPD）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・慢性閉塞性肺疾患（COPD）の中南米市場規模2016-2027（メキシコ、ブラジル） ・慢性閉塞性肺疾患（COPD）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GSK、Pfizer、Merck、Novartis、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceuticals、Ario Pharma、Roche、Ache、Almirall、Aquinox Pharmaceuticals、Asmacure、Astellas Pharma） ・結論 |
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.
The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.
Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disorder Market
The global Chronic Obstructive Pulmonary Disorder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chronic Obstructive Pulmonary Disorder market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chronic Obstructive Pulmonary Disorder market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chronic Obstructive Pulmonary Disorder market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chronic Obstructive Pulmonary Disorder market.
Global Chronic Obstructive Pulmonary Disorder Scope and Market Size
Chronic Obstructive Pulmonary Disorder market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Obstructive Pulmonary Disorder market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Novartis
AstraZeneca
Aquinox Pharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Short-Acting Bronchodilators
1.2.3 Corticosteroids
1.2.4 Methylxanthines
1.2.5 Long-Acting Bronchodilators
1.2.6 Phosphodiesterase-4 Inhibitors
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disorder Market Perspective (2016-2027)
2.2 Chronic Obstructive Pulmonary Disorder Growth Trends by Regions
2.2.1 Chronic Obstructive Pulmonary Disorder Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chronic Obstructive Pulmonary Disorder Historic Market Share by Regions (2016-2021)
2.2.3 Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Regions (2022-2027)
2.3 Chronic Obstructive Pulmonary Disorder Industry Dynamic
2.3.1 Chronic Obstructive Pulmonary Disorder Market Trends
2.3.2 Chronic Obstructive Pulmonary Disorder Market Drivers
2.3.3 Chronic Obstructive Pulmonary Disorder Market Challenges
2.3.4 Chronic Obstructive Pulmonary Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder Players by Revenue (2016-2021)
3.1.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Players (2016-2021)
3.2 Global Chronic Obstructive Pulmonary Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder Revenue
3.4 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder Revenue in 2020
3.5 Chronic Obstructive Pulmonary Disorder Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Disorder Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disorder Historic Market Size by Type (2016-2021)
4.2 Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Type (2022-2027)
5 Chronic Obstructive Pulmonary Disorder Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disorder Historic Market Size by Application (2016-2021)
5.2 Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder Market Size (2016-2027)
6.2 North America Chronic Obstructive Pulmonary Disorder Market Size by Type
6.2.1 North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021)
6.2.2 North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027)
6.2.3 North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2027)
6.3 North America Chronic Obstructive Pulmonary Disorder Market Size by Application
6.3.1 North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021)
6.3.2 North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027)
6.3.3 North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2027)
6.4 North America Chronic Obstructive Pulmonary Disorder Market Size by Country
6.4.1 North America Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021)
6.4.2 North America Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder Market Size (2016-2027)
7.2 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type
7.2.1 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021)
7.2.2 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027)
7.2.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2027)
7.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application
7.3.1 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021)
7.3.2 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027)
7.3.3 Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2027)
7.4 Europe Chronic Obstructive Pulmonary Disorder Market Size by Country
7.4.1 Europe Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021)
7.4.2 Europe Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size (2016-2027)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type
8.2.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2027)
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application
8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2027)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Region
8.4.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder Market Size (2016-2027)
9.2 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type
9.2.1 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021)
9.2.2 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027)
9.2.3 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2027)
9.3 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application
9.3.1 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021)
9.3.2 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027)
9.3.3 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2027)
9.4 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Country
9.4.1 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021)
9.4.2 Latin America Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size (2016-2027)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type
10.2.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2027)
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application
10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2027)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Country
10.4.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Obstructive Pulmonary Disorder Introduction
11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder Introduction
11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Chronic Obstructive Pulmonary Disorder Introduction
11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Obstructive Pulmonary Disorder Introduction
11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder Introduction
11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Introduction
11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Details
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Introduction
11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Ario Pharma
11.8.1 Ario Pharma Company Details
11.8.2 Ario Pharma Business Overview
11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder Introduction
11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.8.5 Ario Pharma Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Chronic Obstructive Pulmonary Disorder Introduction
11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.9.5 Roche Recent Development
11.10 Ache
11.10.1 Ache Company Details
11.10.2 Ache Business Overview
11.10.3 Ache Chronic Obstructive Pulmonary Disorder Introduction
11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.10.5 Ache Recent Development
11.11 Almirall
11.11.1 Almirall Company Details
11.11.2 Almirall Business Overview
11.11.3 Almirall Chronic Obstructive Pulmonary Disorder Introduction
11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.11.5 Almirall Recent Development
11.12 Aquinox Pharmaceuticals
11.12.1 Aquinox Pharmaceuticals Company Details
11.12.2 Aquinox Pharmaceuticals Business Overview
11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Introduction
11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.12.5 Aquinox Pharmaceuticals Recent Development
11.13 Asmacure
11.13.1 Asmacure Company Details
11.13.2 Asmacure Business Overview
11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder Introduction
11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.13.5 Asmacure Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Details
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder Introduction
11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
11.14.5 Astellas Pharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chronic Obstructive Pulmonary Disorder Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Short-Acting Bronchodilators
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Methylxanthines
Table 5. Key Players of Long-Acting Bronchodilators
Table 6. Key Players of Phosphodiesterase-4 Inhibitors
Table 7. Key Players of Others
Table 8. Global Chronic Obstructive Pulmonary Disorder Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Chronic Obstructive Pulmonary Disorder Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Chronic Obstructive Pulmonary Disorder Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2016-2021)
Table 12. Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2022-2027)
Table 14. Chronic Obstructive Pulmonary Disorder Market Trends
Table 15. Chronic Obstructive Pulmonary Disorder Market Drivers
Table 16. Chronic Obstructive Pulmonary Disorder Market Challenges
Table 17. Chronic Obstructive Pulmonary Disorder Market Restraints
Table 18. Global Chronic Obstructive Pulmonary Disorder Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Chronic Obstructive Pulmonary Disorder Market Share by Players (2016-2021)
Table 20. Global Top Chronic Obstructive Pulmonary Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disorder as of 2020)
Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chronic Obstructive Pulmonary Disorder Product Solution and Service
Table 25. Date of Enter into Chronic Obstructive Pulmonary Disorder Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type (2016-2021)
Table 29. Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Chronic Obstructive Pulmonary Disorder Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Application (2016-2021)
Table 33. Global Chronic Obstructive Pulmonary Disorder Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size by Country (2022-2027) & (US$ Million)
Table 65. GSK Company Details
Table 66. GSK Business Overview
Table 67. GSK Chronic Obstructive Pulmonary Disorder Product
Table 68. GSK Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 69. GSK Recent Development
Table 70. Pfizer Company Details
Table 71. Pfizer Business Overview
Table 72. Pfizer Chronic Obstructive Pulmonary Disorder Product
Table 73. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 74. Pfizer Recent Development
Table 75. Merck Company Details
Table 76. Merck Business Overview
Table 77. Merck Chronic Obstructive Pulmonary Disorder Product
Table 78. Merck Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 79. Merck Recent Development
Table 80. Novartis Company Details
Table 81. Novartis Business Overview
Table 82. Novartis Chronic Obstructive Pulmonary Disorder Product
Table 83. Novartis Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 84. Novartis Recent Development
Table 85. AstraZeneca Company Details
Table 86. AstraZeneca Business Overview
Table 87. AstraZeneca Chronic Obstructive Pulmonary Disorder Product
Table 88. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 89. AstraZeneca Recent Development
Table 90. Boehringer Ingelheim Company Details
Table 91. Boehringer Ingelheim Business Overview
Table 92. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Product
Table 93. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 94. Boehringer Ingelheim Recent Development
Table 95. Teva Pharmaceuticals Company Details
Table 96. Teva Pharmaceuticals Business Overview
Table 97. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product
Table 98. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 99. Teva Pharmaceuticals Recent Development
Table 100. Ario Pharma Company Details
Table 101. Ario Pharma Business Overview
Table 102. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 103. Ario Pharma Recent Development
Table 104. Roche Company Details
Table 105. Roche Business Overview
Table 106. Roche Chronic Obstructive Pulmonary Disorder Product
Table 107. Roche Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 108. Roche Recent Development
Table 109. Ache Company Details
Table 110. Ache Business Overview
Table 111. Ache Chronic Obstructive Pulmonary Disorder Product
Table 112. Ache Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 113. Ache Recent Development
Table 114. Almirall Company Details
Table 115. Almirall Business Overview
Table 116. Almirall Chronic Obstructive Pulmonary Disorder Product
Table 117. Almirall Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 118. Almirall Recent Development
Table 119. Aquinox Pharmaceuticals Company Details
Table 120. Aquinox Pharmaceuticals Business Overview
Table 121. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product
Table 122. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 123. Aquinox Pharmaceuticals Recent Development
Table 124. Asmacure Company Details
Table 125. Asmacure Business Overview
Table 126. Asmacure Chronic Obstructive Pulmonary Disorder Product
Table 127. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 128. Asmacure Recent Development
Table 129. Astellas Pharma Company Details
Table 130. Astellas Pharma Business Overview
Table 131. Astellas Pharma Chronic Obstructive Pulmonary Disorder Product
Table 132. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder Business (2016-2021) & (US$ Million)
Table 133. Astellas Pharma Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Obstructive Pulmonary Disorder Market Share by Type: 2020 VS 2027
Figure 2. Short-Acting Bronchodilators Features
Figure 3. Corticosteroids Features
Figure 4. Methylxanthines Features
Figure 5. Long-Acting Bronchodilators Features
Figure 6. Phosphodiesterase-4 Inhibitors Features
Figure 7. Others Features
Figure 8. Global Chronic Obstructive Pulmonary Disorder Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Chronic Obstructive Pulmonary Disorder Report Years Considered
Figure 13. Global Chronic Obstructive Pulmonary Disorder Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Chronic Obstructive Pulmonary Disorder Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions: 2020 VS 2027
Figure 16. Global Chronic Obstructive Pulmonary Disorder Market Share by Regions (2022-2027)
Figure 17. Global Chronic Obstructive Pulmonary Disorder Market Share by Players in 2020
Figure 18. Global Top Chronic Obstructive Pulmonary Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disorder as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder Revenue in 2020
Figure 20. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type (2016-2021)
Figure 21. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type (2022-2027)
Figure 22. North America Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Chronic Obstructive Pulmonary Disorder Market Share by Type (2016-2027)
Figure 24. North America Chronic Obstructive Pulmonary Disorder Market Share by Application (2016-2027)
Figure 25. North America Chronic Obstructive Pulmonary Disorder Market Share by Country (2016-2027)
Figure 26. United States Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Chronic Obstructive Pulmonary Disorder Market Share by Type (2016-2027)
Figure 30. Europe Chronic Obstructive Pulmonary Disorder Market Share by Application (2016-2027)
Figure 31. Europe Chronic Obstructive Pulmonary Disorder Market Share by Country (2016-2027)
Figure 32. Germany Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Chronic Obstructive Pulmonary Disorder Market Share by Region (2016-2027)
Figure 42. China Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Chronic Obstructive Pulmonary Disorder Market Share by Type (2016-2027)
Figure 50. Latin America Chronic Obstructive Pulmonary Disorder Market Share by Application (2016-2027)
Figure 51. Latin America Chronic Obstructive Pulmonary Disorder Market Share by Country (2016-2027)
Figure 52. Mexico Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Chronic Obstructive Pulmonary Disorder Market Share by Country (2016-2027)
Figure 58. Turkey Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Chronic Obstructive Pulmonary Disorder Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 63. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 65. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 67. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 68. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 69. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 70. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 71. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 72. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 73. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 74. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disorder (COPD) Market The global Chronic Obstructive Pulmonary Disorder (COPD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy…- 世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eve…
- 世界の慢性閉塞性肺疾患（COPD）治療薬市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful …
- 世界の慢性うつ病パーソナリティ障害治療市場規模・現状・予測（2021年-2027年） Chronic depressive personality disorder also known as Dysthymia is a chronic form of depression. It is mild form of depression which last up to two years or more. This disorder is less severe in comparison to other forms of depression. Symptoms of chronic depressive personality disorder are loss of …
- 世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場規模・現状・予測（2021年-2027年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…